- About Us
- Services & Solutions
- Bioconjugation Discovery
- Bioconjugation Process Development
- Analytical Development
- Formulation and DP Development
- GMP mAb Intermediate and Conjugation Manufacturing
- GMP Formulation, Fill and Lyophilization
- Payload and Linker R&D and Manufacturing
- Ready-Made Payloads & Linkers
- Your Frontier Technology Platform For Bioconjugates
- Investor Relations
- News & Resources
WuXi Biologics
Offering End-to-End Solutions
- About Us
About Us - Services & SolutionsAbout Us
- Investor RelationsAbout Us
- News & ResourcesAbout Us
Versatile Drug-to-Antibody Ratio Options with WuXiDARx™
Proprietary Conjugation Technology
WuXiDARx™, our proprietary conjugation technology targeting the clinically validated interchain cysteine sites, delivers exceptional flexibility in drug-to-antibody ratio (DAR) and demonstrates high homogeneity. It is compatible with native IgG1 antibodies and a wide range of common payload linker and significantly simplifies the CMC process.
The technology delivers significant value across the development continuum: when screening antibody and payload-linker combinations, it streamlines ADC engineering and facilitates optimal DAR identification. At the CMC stage, it accelerates development, mitigates risks, and reduces large-scale manufacturing costs.
Enable Versatility across Diversified Bioconjugates beyond Conventional ADCs
Ideal for Your Antibody-Oligonucleotide Conjugates
- High purity: Up to ~ 90% D1 species before column purification
- Simple process: Chemical conjugation, comparable with symmetrical antibody, no sequence engineering or enzymatic reaction required
- Good efficacy: Higher siRNA in target tissue and stronger DMPK silence efficiency in mouse
Robust and Validated Conjugation Technology
ADCs produced from WuXiDAR4 demonstrated comparable cytotoxicity to ADCs produced by conventional random conjugation methods, but demonstrate better pharmacokinetics (PK) profiles and tolerability. So far, 7 ADC molecules that WuXiDAR4 has generated have entered clinical trials.
Improved Efficacy and Tolerability
WuXiDAR4 technology features an enhanced high-homogeneity DAR 4 profile. ADCs engineered with the technology demonstrate superior PK and in vivo efficacy relative to ADCs achieving DAR 4 via conventional random cysteine conjugation.
10
+
CMC projects
7
Clinicla-stage ADC molecules
2
kg+
GMP batches prepared
Notice:
You are leaving WuXi Biologics Website, after which our Privacy Notice will not apply. Please keep it in mind the protection of your privacy. Are you willing to proceed?